Paper · 41809520
Advancing hepatology through innovation and integration: iLIVER's vision for 2026.
Du ZC and 5 others. ILIVER, 2026. Cited by 0 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Advancing hepatology through innovation and integration: iLIVER's vision for 2026. Papers, record 41809520. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41809520
On this page
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Grants0
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
None in this release.
Trials0
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
None in this release.
Comments and corrections0
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
None in this release.
References8
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 41,399,682 | Bile cell-free DNA shows benefit as a potential sample for somatic mutation detection of resectable cholangiocarcinoma. | ILIVER | 2025 | https://conductscience.org/library/papers/41399682 | PubMed |
| 2 | 39,986,353 | Hepatocellular carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. | Ann Oncol | 2025 | https://conductscience.org/library/papers/39986353 | PubMed |
| 3 | 41,362,693 | Personalized management of metabolic dysfunction-associated steatotic liver disease. | ILIVER | 2025 | https://conductscience.org/library/papers/41362693 | PubMed |
| 4 | 41,054,418 | Technical advances and application strategies in anatomical hepatic resection based on Laennec's capsule. | ILIVER | 2025 | https://conductscience.org/library/papers/41054418 | PubMed |
| 5 | 40,636,457 | Efficacy analysis of hepatic arterial infusion chemotherapy combined with sintilimab and bevacizumab for initially unresectable hepatocellular carcinoma. | ILIVER | 2025 | https://conductscience.org/library/papers/40636457 | PubMed |
| 6 | 41,054,419 | AI-driven multimodal fusion of tongue images and clinical indicators for identifying MAFLD patients at risk of coronary artery disease: An exploratory study. | ILIVER | 2025 | https://conductscience.org/library/papers/41054419 | PubMed |
| 7 | 40,636,461 | Challenges and progress in techniques of precision liver surgery. | ILIVER | 2025 | https://conductscience.org/library/papers/40636461 | PubMed |
| 8 | 40,636,460 | Multiphase MRI radiomics model for predicting microvascular invasion in HCC: Development and clinical validation. | ILIVER | 2025 | https://conductscience.org/library/papers/40636460 | PubMed |
Cited by0
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 0 citations.
None in this release.
Genes0
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
None in this release.
Drugs0
The drugs whose trials, in the Pipelines release, list the paper.
None in this release.
Data0
The data bank entries PubMed's record names. Trial numbers are under Trials.
None in this release.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41809520
GET https://conductscience.org/api/papers/v1/41809520/authors